Splisense Company
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.
Technology:
Gene Therapy
Industry:
Geroscience
Headquarters:
Jerusalem, Yerushalayim, Israel
Founded Date:
2016-01-01
Employees Number:
1-10
Funding Status:
Seed
Investors Number:
5
Total Funding:
28500000
Last Funding Date:
2021-05-13
Last Funding Type:
Series B
Register and Claim Ownership